$BRO

Brown & Brown (NYSE:BRO) reports sales below analyst estimates in Q3 2026 earnings

Brown & Brown (BRO) reported Q3 2026 revenue of $1.73B, missing estimates by 2.1% but up 7.4% YoY. Adjusted EPS of $1.07 missed estimates by 1.4%. The company cited customer growth despite a challenging rate environment and recent acquisitions. Analysts expect 4.2% revenue growth over the next 12 months, with EPS projected to rise 6.3%.

Original reporting
Published Oct 26, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Brown & Brown (NYSE:BRO) reports sales below analyst estimates in Q3 2026 earnings — source image
Decision brief

The 30-second read

$BROBearishMed
01

Why it matters

The earnings miss may trigger sell‑offs in the stock and prompt analysts to lower near‑term outlooks.

02

Market read

First‑time earnings disclosure for Q3 2026; material for traders watching insurance brokerage stocks.

03

What to watch

Recent hiring of 5,000 teammates from Accession may bolster future growth despite the current quarter's miss.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

Brown & Brown is a mid‑cap insurance brokerage with a market cap of $24.4 B. The Q3 release showed 7.4% YoY revenue growth but missed consensus estimates.

Company-level read

Ticker impact

$BROBearishHigh confidence
Context

Brown & Brown reported Q3 2026 revenue and EPS that missed analyst estimates, causing a 1.8% share decline.

Expected impact

likely downward pressure as the market prices in the revenue and EPS shortfall

Evidence & confidence

Both revenue and adjusted EPS fell short of consensus, and the stock slid 1.8% immediately after release.

Market effects

The insurance brokerage sector may see broader scrutiny as peers' earnings expectations are reassessed.

U.S. market participants may adjust exposure to mid‑cap insurance firms.

Limited to U.S. equities; no direct global macro impact.

Counterpoint

The miss could be a short‑term overreaction; the company's long‑term revenue growth remains strong.

Key entities

  • J. Powell Brown

    President and CEO who commented on the quarter's performance.

Related articles

$BROHighAI 8/10

Why Brown & Brown Stock Slumped by 5% Today

Brown & Brown (BRO) stock fell 5% after Q3 earnings missed estimates. Revenue rose 7% YoY to $1.73B, below the $1.76B consensus. GAAP net income increased 6% to $240M, while adjusted EPS grew 2% to $1.07, missing the $1.09 estimate. The company cited a challenging rate environment and attributed some growth to its Accession acquisition, but organic revenue grew only 1% YoY to $1.46B.

$BROMed

Brown & Brown Inc (BRO) (Q3 2026) Earnings Call Highlights: Revenue Up 7.4%

Brown & Brown Inc (BRO) reported Q3 2026 revenue up 7.4% to $1.07B, but adjusted EBITDAC margin fell 200 bps to 34.6%. Specialty Distribution organic revenue declined 0.8%, missing expectations due to competition and pricing pressures. The company anticipates further declines in Q4 and faces ongoing litigation impacts. Integration costs for Accession have increased to $250-300M.

$BROMed

What Brown & Brown (BRO) Said on Its Q3 Earnings Call

Brown & Brown (BRO) reported Q3 earnings, noting market shifts in California and Texas, and pricing pressures in commercial earthquake business. The company expects 2027 growth of 2%-4% for retail and 1%-3% for specialty distribution. Accession acquisition raised synergy targets to $50M for 2026 and $175M by 2028. AI initiatives are expanding across the company, with tools like Claude and COMPASS being deployed. The board increased the dividend by 9%.

$BROHighAI 8/10

Brown & Brown (BRO) Q3 2026 Earnings Call Transcript

Brown & Brown (BRO) reported Q3 2026 revenues of $1.7B, up 7.4% YoY. Organic revenue grew 1.2%, while adjusted EBITDAC margin fell 200 bps to 34.6%. Adjusted EPS rose 2% to $1.07. The company raised its dividend by 9%, marking 33 consecutive years of increases. Retail segment outperformed expectations, while specialty distribution faced headwinds. The company repurchased $750M in shares YTD, including $250M in Q3.

$BROMed

Truist cuts Brown & Brown stock price target to $85 on lower estimates

Truist Securities reduced its price target for Brown & Brown (NYSE:BRO) to $85 from $90, citing lower 2026 and 2027 EPS estimates. The firm maintained a Buy rating, basing the target on a 14x multiple of its 2027 EBITDA estimate. BRO's Q3 earnings missed expectations, with revenue at $1.72B and EPS at $1.07, though both showed year-over-year growth. The company's organic growth slowed, and its adjusted EBITDAC margin declined by 200 basis points.